Celgene Corporation (CELG) Stake Lifted by Abner Herrman & Brock LLC
Abner Herrman & Brock LLC lifted its position in shares of Celgene Corporation (NASDAQ:CELG) by 0.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,129 shares of the biopharmaceutical company’s stock after acquiring an additional 83 shares during the quarter. Celgene Corporation accounts for approximately 1.4% of Abner Herrman & Brock LLC’s portfolio, making the stock its 28th largest holding. Abner Herrman & Brock LLC’s holdings in Celgene Corporation were worth $7,549,000 at the end of the most recent quarter.
Other institutional investors have also recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Celgene Corporation during the first quarter worth about $118,000. Oakworth Capital Inc. increased its stake in shares of Celgene Corporation by 60.9% during the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after acquiring an additional 412 shares during the period. Acropolis Investment Management LLC acquired a new position in shares of Celgene Corporation during the second quarter worth about $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 380 shares during the period. Finally, RB Capital Management LLC acquired a new position in shares of Celgene Corporation during the second quarter worth about $202,000. Institutional investors and hedge funds own 79.33% of the company’s stock.
Shares of Celgene Corporation (NASDAQ CELG) traded up 2.14% during mid-day trading on Friday, reaching $145.82. 4,324,637 shares of the company traded hands. The stock’s 50 day moving average is $135.45 and its 200 day moving average is $127.81. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $146.00. The stock has a market capitalization of $114.08 billion, a PE ratio of 45.16 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. During the same period in the previous year, the firm earned $1.44 EPS. Celgene Corporation’s revenue was up 18.7% on a year-over-year basis. On average, analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current year.
In other news, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction that occurred on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the transaction, the director now directly owns 76,301 shares of the company’s stock, valued at $10,264,010.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the transaction, the director now directly owns 69,424 shares in the company, valued at $9,061,220.48. The disclosure for this sale can be found here. Insiders sold a total of 46,233 shares of company stock worth $6,268,259 in the last ninety days. Corporate insiders own 0.95% of the company’s stock.
CELG has been the topic of several recent analyst reports. BTIG Research lowered shares of Celgene Corporation from a “buy” rating to a “neutral” rating and upped their target price for the stock from $96.93 to $131.70 in a research report on Friday, June 30th. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price on the stock in a research report on Thursday, August 10th. SunTrust Banks, Inc. set a $150.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 6th. Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 27th. Finally, William Blair restated an “outperform” rating on shares of Celgene Corporation in a research report on Monday, June 26th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the stock. Celgene Corporation presently has a consensus rating of “Buy” and a consensus price target of $150.31.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.